Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 most active penny stocks to buy. Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout On March 13, 2026, Biren Amin, an analyst at Piper Sandler, maintained an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) and increased the price target of the stock from $7 to $8. Amin noted increased anticipation surrounding the company’s upcoming clinical catalyst. The interim analysis of the Phase ...

Core Insights - Allogene Therapeutics (ALLO) reported a narrower fourth-quarter 2025 loss of 17 cents per share, compared to the Zacks Consensus Estimate of a loss of 25 cents and a loss of 28 cents in the same quarter last year [1][5] - The company's shares have increased by 80% year-to-date, significantly outperforming the industry average growth of 4% [1] Financial Performance - Research and development (R&D) expenses for Q4 2025 were $28.6 million, a decrease of 36% from the previous year [3] - General and administrative (G&A) expenses fell by 11% year-over-year to $13.8 million [3] - Allogene ended 2025 with $258.3 million in cash and cash equivalents, down from $277 million as of September 30, 2025, which is expected to fund operations into the first quarter of 2028 [3] Annual Results - For the full year 2025, Allogene did not record any revenues and reported a loss of 87 cents per share, an improvement from the loss of $1.32 per share in the previous year [4] 2026 Guidance - The company anticipates full-year operating expenses to be around $210 million, including nearly $35 million in non-cash stock-based compensation [6] - Cash burn for the full year is expected to be approximately $150 million [6] Pipeline Updates - Allogene's primary focus is on the pivotal phase II ALPHA3 study evaluating cema-cel for treating newly diagnosed large B-cell lymphoma patients, with data expected in April 2026 [7] - The company has initiated the phase I RESOLUTION basket study for ALLO-329 in various autoimmune diseases, with initial data expected in June 2026 [8] - Allogene is also developing ALLO-316, currently in the phase I TRAVERSE study for advanced renal cell carcinoma, and is exploring partnership opportunities for its development [9]

Core Insights - Allogene Therapeutics is positioning 2026 as a pivotal year, aiming to achieve significant clinical milestones with a focus on speed and rigor [2] - The company is committed to validating its allogeneic platform, emphasizing its role as a primary solution rather than an alternative [2] Financial Outlook - Allogene has extended its cash runway into 2028, indicating a strong financial position to support ongoing and future projects [2] - The company is prioritizing scalable CAR T programs, which are expected to drive growth and innovation in its therapeutic offerings [2]

Chief Medical Officer Dr. Zachary Roberts described ALPHA3 as the first randomized lymphoma study designed to test whether early minimal residual disease (MRD)-guided consolidation with an allogeneic CAR T can prevent relapse. In the trial, patients who achieve remission after standard first-line therapy undergo ctDNA testing; those who are MRD-positive are randomized to observation or treatment with cema-cel.Chang said Allogene is prioritizing programs where it believes allogeneic CAR T’s advantages—scalab ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash equivalents and investments of $258.3 million, with an additional $23.7 million received from a favorable arbitration outcome [15][16] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, while the full year net loss was $189.9 million, or $0.87 per share [17][18] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [16][18] Business Line Data and Key Metrics Changes - The focus for 2026 is on delivering clinical milestones for two key programs: cema-cel in ALPHA3 and ALLO-329 in RESOLUTION [5][10] - ALPHA3 aims to redefine management of large B-cell lymphoma by testing early MRD-guided consolidation with allogeneic CAR T therapy [10][11] - ALLO-329 is designed for autoimmune diseases, with initial proof of concept data expected in June 2026 [12][14] Market Data and Key Metrics Changes - The company is expanding its clinical trials into community cancer centers, which have historically been excluded from offering CAR T therapies [11][12] - Over 60 active sites across the U.S. and Canada are involved in the ALPHA3 study, with plans for expansion into Australia and South Korea [11][12] Company Strategy and Development Direction - The company aims to validate its allogeneic platform as a scalable and accessible cell therapy option [5][8] - There is a focus on disciplined execution and prioritization of resources towards programs with the greatest potential [8][14] - The company is positioned to execute through critical proof points in 2026, with a cash runway extended into the first quarter of 2028 [8][18] Management's Comments on Operating Environment and Future Outlook - Management believes the cell therapy environment is shifting towards evidence-based outcomes, emphasizing data and disciplined execution [5][6] - The company is optimistic about the potential of its allogeneic CAR T therapies to expand access and improve patient outcomes [5][8] - Management is focused on generating data that clearly defines the role of allogeneic CAR T in oncology and autoimmune diseases [14][18] Other Important Information - The company has made prudent use of its ATM equity facility, raising an additional $20.7 million year to date [15][16] - Guidance for operating cash expenses in 2026 is expected to be approximately $150 million, with GAAP operating expenses around $210 million [18] Q&A Session Summary Question: Can you elaborate on the safety parameters for the ALPHA3 data update? - Management plans to provide high-level safety information, focusing on serious adverse events and outpatient delivery feasibility [22][23] Question: What read-throughs do you have from the recent ZUMA-7 MRD analysis? - Management views the ZUMA-7 study as consistent with their expectations for MRD clearance and its correlation to clinical outcomes [26][27] Question: What is the expected rate of spontaneous MRD conversion in the observation arm of ALPHA3? - Management has modeled a spontaneous clearance rate of about 20%, expecting 2-3 patients to potentially convert from MRD positive to negative [46][50] Question: How many community centers in the ALPHA3 study had prior CAR T or transplant capabilities? - Approximately 50% of the sites are community practices, with some being CAR T naive and successfully enrolling patients [62][63] Question: Will you present data on CD70 positive T cell depletion in ALLO-329? - Management indicated that translational data will be collected and analyzed, focusing on the 20 million cell dose level [68][70]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash equivalents and investments of $258.3 million, with an additional $23.7 million received from a favorable arbitration outcome [13][14] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, while the full year net loss was $189.9 million, or $0.87 per share [16][17] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [15][17] Business Line Data and Key Metrics Changes - The focus for 2026 is on delivering clinical milestones for cema-cel in ALPHA3 and ALLO-329 in RESOLUTION, with significant emphasis on the allogeneic CAR T platform [4][6] - ALPHA3 aims to redefine management of large B-cell lymphoma by testing early intervention with cema-cel [5][8] - ALLO-329 is designed for autoimmune diseases, targeting CD19 and CD70, with proof of concept data expected in June 2026 [6][10] Market Data and Key Metrics Changes - The company has over 60 active clinical sites across the U.S. and Canada, with plans to expand to Australia and South Korea [9] - The integration of cema-cel into community cancer centers is seen as a core advantage, expanding access to advanced cell therapy [9] Company Strategy and Development Direction - The company aims to validate its allogeneic platform as a scalable and accessible solution for cell therapy [4][6] - There is a strategic focus on prioritizing resources for programs with the greatest potential for demonstrating the advantages of allogeneic CAR T [6][12] - The company is positioned for long-term value creation with a cash runway extended into the first quarter of 2028 [15][17] Management's Comments on Operating Environment and Future Outlook - Management believes that the cell therapy landscape is shifting towards evidence-based practices, emphasizing data and disciplined execution [4] - The upcoming year is viewed as critical for generating proof points that could validate the allogeneic platform [4][6] - Management expressed confidence in the ability to execute through important inflection points with a focus on high-impact programs [17][18] Other Important Information - The company has made prudent use of its ATM equity facility, raising an additional $20.7 million year to date [14] - Guidance for operating cash expenses in 2026 is expected to be approximately $150 million, with GAAP operating expenses around $210 million [17] Q&A Session Summary Question: Safety parameters for ALPHA3 data update - Management plans to provide high-level safety information, focusing on serious adverse events and outpatient delivery feasibility [20][21] Question: Insights from ZUMA-7 MRD analysis - Management views the ZUMA-7 study as consistent with their expectations for MRD clearance and its correlation to clinical outcomes [23][24] Question: Interim analysis and MRD conversion - Management indicated that while MRD clearance may correlate with clinical outcomes, the relationship is not fully established [28][29] Question: Expectations for ALLO-329 data - The target product profile for ALLO-329 includes low or no lymphodepletion, with ongoing studies testing these parameters [31][32] Question: Market opportunity and stem cell positioning - Management is monitoring the evolving landscape of large B-cell lymphoma treatments and believes MRD positivity rates will remain largely unchanged [34][36] Question: Enrollment pace for ALPHA3 study - Enrollment is on track to be completed by the end of 2027, with MRD positivity rates consistent with expectations [67][68]

Financial Performance - The company incurred net losses in every period since inception and anticipates substantial net losses in the future[26]. - The company must obtain substantial additional financing to develop products and implement operating plans[26]. Cash and Investments - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $258.3 million[654]. - A 10% change in interest rates would not have had a material effect on the fair market value of the company's cash equivalents and available-for-sale securities[654]. Risks and Dependencies - The company faces foreign exchange risk due to collaboration payments required in euros, with a potential impact from adverse movements in foreign exchange rates[655]. - The company relies on third parties for clinical trials, and any failure to meet contractual duties could hinder regulatory approval and commercialization[27]. - The company is heavily dependent on the success of its lead product candidates, which are based on novel technologies[26]. - The company has incurred risks related to serious adverse events in clinical trials, which could lead to regulatory actions and negative perceptions[26]. - The FDA approval process is lengthy, and significant delays may occur in the clinical development and regulatory approval of product candidates[31]. - The company is reliant on key personnel, and failure to attract and retain qualified personnel may hinder business strategy implementation[26].

Financial Performance - Allogene ended Q4 2025 with $258.3 million in cash, cash equivalents, and investments, extending its cash runway into Q1 2028[8]. - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year, which includes $12.9 million of non-cash stock-based compensation[18]. - General and administrative expenses for Q4 2025 were $13.8 million, totaling $56.8 million for the full year, which includes $24.7 million of non-cash stock-based compensation[18]. - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, with a full-year net loss of $190.9 million, or $0.87 per share[18]. - The company anticipates operating cash expenses of approximately $150 million for 2026, with GAAP operating expenses expected to be around $210 million[14]. Clinical Trials and Research - The pivotal Phase 2 ALPHA3 trial of cema-cel is designed to evaluate whether early, MRD-guided consolidation can prevent recurrence of large B-cell lymphoma (LBCL)[4]. - The interim futility analysis for the ALPHA3 trial is planned for April 2026, comparing MRD clearance rates between cema-cel and observation[6]. - ALLO-329, a dual-targeted CAR T therapy, is currently in the Phase 1 RESOLUTION trial, with proof-of-concept data expected in June 2026[10]. Strategic Initiatives - Allogene is exploring partnering opportunities for ALLO-316, which has shown significant response rates in metastatic solid tumors[11]. - The company aims to deliver allogeneic CAR T therapy at biologic-like scale, enhancing access across both academic and community care settings[19].

Core Insights - Allogene Therapeutics is at a critical juncture with the upcoming interim data from the ALPHA3 trial of cema-cel, which aims to determine if early, MRD-guided allogeneic CAR T therapy can prevent relapse in large B-cell lymphoma (LBCL) [2][3] - The company is focused on demonstrating that allogeneic CAR T can be delivered at a biologic-like scale, moving beyond academic settings [2][4] - Allogene has a cash runway extending into Q1 2028, allowing for disciplined execution and data delivery across its portfolio [2][13] Company Updates - The ALPHA3 trial is designed to evaluate cema-cel as a "7th cycle" of first-line therapy, integrating it without altering existing treatment workflows [4] - The trial is enrolling patients at over 60 clinical sites, including both academic and community cancer centers, to enhance patient access [4] - An interim futility analysis is scheduled for April 2026, which will compare MRD clearance rates between cema-cel and observation [5] Product Development - ALLO-329 is a next-generation allogeneic CAR T therapy targeting CD19/CD70, utilizing proprietary Dagger technology for built-in lymphodepletion [6][10] - The Phase 1 RESOLUTION trial for ALLO-329 is currently enrolling patients across multiple autoimmune indications, with proof-of-concept data expected in June 2026 [7][10] - ALLO-316 has shown significant response rates in metastatic solid tumors, with the TRAVERSE trial completed and the company exploring partnership opportunities [11] Financial Performance - As of December 31, 2025, Allogene reported $258.3 million in cash, cash equivalents, and investments, extending its cash runway into Q1 2028 [12][13] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [16] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, with a full-year net loss of $190.9 million, or $0.87 per share [16][22]

Summary of Allogene Therapeutics FY Conference Call Company Overview - **Company**: Allogene Therapeutics (NasdaqGS:ALLO) - **Industry**: Biotechnology, specifically focused on allogeneic CAR-T cell therapy Core Points and Arguments 1. **Advancement of Allogene XL Therapy**: Allogene has been developing its Allogene XL therapy for eight years, emphasizing its potential as a one-time treatment that could lead to durable responses and possibly cure diseases [2][3][4] 2. **Patient Accessibility**: The company is focused on improving patient access by eliminating logistics associated with autologous cell therapy and bringing treatments to community-based cancer centers [3][4] 3. **Manufacturing Capabilities**: Allogene estimates it can produce 20,000-60,000 patient doses annually at a cost of goods between $10,000-$20,000, which is a significant improvement in cell therapy economics [4][5] 4. **Unique Advantages of Allogeneic CAR-T**: The company highlights the unique advantages of its allogeneic CAR-T therapy, including multiplex gene editing capabilities that competitors lack [4][5] 5. **Key Programs**: - **Cema-cel CD19 Program**: Focused on MRD-directed therapy for large B-cell lymphoma, with initial data expected in April 2026 [6][8] - **ALLO-329 Program**: A dual CD19, CD70 program targeting rheumatologic disorders, with proof of concept data expected in June 2026 [6][17] - **ALLO-316 Program**: A CD70 directed program for renal cell cancer, with proof of concept data already generated [7] Clinical Insights 1. **MRD Testing**: The company is utilizing circulating tumor DNA (MRD assay) to predict disease recurrence in patients post-R-CHOP treatment, which is crucial for the ALPHA3 study [8][9][12] 2. **Study Design**: The ALPHA3 study will enroll approximately 220 MRD-positive patients, with primary endpoints focused on event-free survival (EFS) and secondary endpoints including progression-free survival (PFS) and overall survival [13][14] 3. **Interim Futility Analysis**: An interim futility analysis is planned, with a target of 25%-30% improvement in MRD clearance as a benchmark for success [14][20] 4. **Market Opportunity**: The total addressable market (TAM) for MRD-positive patients post-R-CHOP is estimated at $5 billion, with potential peak sales exceeding $2 billion [37] Safety and Administration 1. **Outpatient Administration**: The company aims to demonstrate that cema-cel can be safely administered as an outpatient treatment, which is a significant advantage for patient management [25][34] 2. **Safety Profile**: Initial studies indicate a favorable safety profile, with no high-grade CRS or ICANS reported in previous trials [34] Future Directions 1. **Expansion into Autoimmune Indications**: The ALLO-329 program is designed to address autoimmune diseases, with potential applications in various conditions such as SLE, myositis, and scleroderma [17][48] 2. **Potential for Pivotal Studies**: The company is considering various autoimmune indications for future pivotal studies, including IgA nephropathy and multiple sclerosis [48] Underappreciated Aspects 1. **Transformative Potential of ALPHA3 Study**: The potential impact of the ALPHA3 study on frontline lymphoma treatment is significant but may not be fully recognized by investors [50] 2. **Advancements in Allogeneic Cell Therapy**: Despite recent setbacks in the industry, Allogene is positioned to make substantial progress in allogeneic cell therapy, which may be overlooked by the market [52]